✦ LIBER ✦

Combination of ziprasidone and clozapine in treatment-resistant schizophrenia

✍ Scribed by M. Zink; E. Mase; H. Dressing

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 57 KB
Volume: 19
Category: Article
ISSN: 0885-6222
DOI: 10.1002/hup.580

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

In cases of treatment‐resistant schizophrenia the combined application of antipsychotic drugs often becomes necessary. Clozapine has been combined successfully with other atypical antipsychotic drugs such as risperidone or amisulpride in the past.

We report the difficult treatment of a 28‐year‐old schizophrenic woman. Psychotic symptoms were found resistant to monotherapy with clozapine or ziprasidone. In contrast, combined application led to a marked improvement in both positive and negative symptoms of schizophrenia along with a decrease of side effects.

📜 SIMILAR VOLUMES

Reasons for non-prescription of clozapin

Reasons for non-prescription of clozapine in treatment-resistant schizophrenia

✍ M. Swinton; A.G. Ahmed 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Background Patients in special hospitals who are suffering from schizophrenia have lengthy admissions and this is primarily as a result of poor response to standard neuroleptics. Clozapine has a specific licence for use in such cases yet a significant proportion of special hospital patients have nev

Ziprasidone as an adjuvant for clozapine

Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia

✍ David C. Henderson; Xiaoduo Fan; Paul M. Copeland; Bikash Sharma; Christina P. B 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

## Abstract ## Objective This study sought to examine the effect of ziprasidone on olanzapine or clozapine‐associated medical morbidity such as insulin resistance, diabetes mellitus (DM) and impaired fasting glucose, obesity, and hyperlipidemia in patients with schizophrenia or schizoaffective dis

Clozapine-induced decrease in the produc

Clozapine-induced decrease in the production of reactive oxygen metabolites by monocytes in vitro may predict clinical response to clozapine in treatment-resistant schizophrenia

✍ Grigori Joffe; Peter Nyberg; Andres Gross; Björn Appelberg 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

Reactive oxygen metabolites (ROM), produced by mononuclear phagocytes may participate in brain pathology. Clozapine (CLO) may modulate cell immunity, and it is also superior to conventional neuroleptics in conditions with a putative impact of oxidative damage by ROM, i.e. negative symptoms and neuro

The sequential treatment approach to res

The sequential treatment approach to resistant schizophrenia with risperidone and clozapine: results of an open study with follow-up

✍ R. Cavallaro; P. Brambilla; E. Smeraldi 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 2 views

In this paper we extend and test with long-term follow-up the results of a previous paper on the usefulness of a sequential treatment protocol with risperidone and clozapine in resistant schizophrenia. Twenty-four patients diagnosed as resistant schizophrenics according to DSM III R and Kane et al.

A pilot, open study on the treatment of

A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine

✍ Roberto Cavallaro; Cristina Colombo; Enrico Smeraldi 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 273 KB 👁 2 views

The aim of this report is to show the results of a pilot, open label treatment programme for resistant schizophrenia in which risperidone was used before clozapine. Thirteen DSM I11 R, drug resistant schizophrenics were treated with risperidone p.0. at doses up to 16 mg/day for three months. Clinica

Combination immunosuppressive treatment

Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis

✍ Daniel J. Wallace; Allan L. Metzger; Kathy K. White 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB